Troglitazone-d4

Troglitazone-d4 is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

Product Specifications

CAS Number

[2749370-85-0]

Product Name Alternative

CS-045-d4

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Autophagy; Ferroptosis; Isotope-Labeled Compounds; PPAR

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.19

Solubility

10 mM in DMSO

Smiles

O=C1SC(CC2=C([2H])C([2H])=C(C([2H])=C2[2H])OCC3(C)OC4=C(CC3)C(C)=C(O)C(C)=C4C)C(N1)=O

Molecular Formula

C24H23D4NO5S

Molecular Weight

445.56

Precautions

H302

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Fujita M, et al. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer Res. 2017 Jul 3;36 (1) :91.|[3]Nazim UM, et al. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017 Apr 18;8 (16) :26819-26831.|[4]Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43 (4) :527-50.